Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–182 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tetanus Toxoid Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769
View directory record Official record
Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 26 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 2 Interventional

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

NCT00938223
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide and 12-peptide melanoma vaccines
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

NCT00003222
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tetanus peptide melanoma vaccine, tyrosinase peptide
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 10, 2026, 12:47 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer

NCT00027833
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ALVAC-CEA-B7.1 vaccine, tetanus toxoid, FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Biological · Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 10, 2026, 12:47 AM EDT
Terminated Phase 1 Interventional

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145
View directory record Official record
Conditions
Melanoma
Interventions
A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

NCT01732627
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
Interventions
Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Scottsdale, Arizona • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

NCT01439165
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine, Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
31
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

NCT01738477
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 30 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
20
States / cities
Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

NCT02737475
View directory record Official record
Conditions
Advanced Cancer
Interventions
BMS-986178, Nivolumab, Ipilimumab, Tetanus vaccine, DPV-001 vaccine, Cyclophosphamide
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix™, Infanrix™, ActHIB™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 10, 2026, 12:47 AM EDT
Terminated Phase 1 Interventional

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

NCT00369291
View directory record Official record
Conditions
Germ Cell Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
keyhole limpet hemocyanin, tetanus toxoid
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program

NCT02673255
View directory record Official record
Conditions
Healthy
Interventions
Tetanus and Diphtheria (Td) Vaccine
Biological
Lead sponsor
Biomat USA, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Bellflower, California • Lincoln, Nebraska • Clarksville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 10, 2026, 12:47 AM EDT
Completed Not applicable Interventional

DTaP and Apnea/Bradycardia in Preterm Infants

NCT00482781
View directory record Official record
Conditions
Prolonged Apnea, Prolonged Bradycardia
Interventions
Infanrix, Pediatrix
Biological
Lead sponsor
American SIDS Institute
Other
Eligibility
56 Days to 60 Days
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
10
States / cities
Austell, Georgia • Marietta, Georgia • Belle Mead, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2007 · Synced Oct 10, 2026, 12:47 AM EDT